Sangamo Therapeutics, Inc.

PIONEERING GENETIC CURES

For Sangamo Therapeutics, science is a means to develop new medicines to transform the lives of patients living with serious genetic diseases.

Learn More

DEVELOPING THE MOST ADVANCED AND PRECISE GENOMIC MEDICINES

With 21 years of experience, Sangamo is a pioneer in research and development of new gene-based therapies.

Learn More

MEETING THE NEEDS OF PATIENTS WITH COMMITMENT AND COMPASSION

We seek to gain perspectives from patients, caregivers and their advocates in order to understand the daily challenges of those we are here to serve.

Learn More

A Multi-Platform Approach to Gene-Based Therapeutics

Industry leading technologies in gene therapy, genome editing, cell therapy and gene regulation

Gene Therapy

Gene Therapy
Genome Editing

Genome Editing
Cell Therapy

Cell Therapy
Gene Regulation

Gene Regulation

News + Events

September 5, 2018

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

August 30, 2018

Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences

August 10, 2018

Sangamo Therapeutics Announces Presentation At The 2018 Wedbush PacGrow Healthcare Conference

View All